2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis§

Authors


  • The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

  • Members of the Task Force Panel: Claire Bombardier, MD, MSc (University of Toronto, Toronto, Ontario, Canada), Arthur F. Kavanaugh, MD (University of California, San Diego), Dinesh Khanna, MD, MSc (University of Michigan, Ann Arbor), Joel M. Kremer, MD (Albany Medical Center, Albany, NY), Amye L. Leong, MBA (Healthy Motivation, Santa Barbara, CA), Eric L. Matteson, MD, MPH (Mayo Clinic, Rochester, MN), John T. Schousboe, MD, PhD (Park Nicollet Clinic and University of Minnesota, Minneapolis), Charles M. King, MD (North Mississippi Medical Center, Tupelo), Maxime Dougados, MD (Hôpital Cochin, Paris, France), Eileen Moynihan, MD (Highmark Medicare Services, Woodbury, NJ), Karen S. Kolba, MD (Pacific Arthritis Center, Santa Maria, CA).

  • §

    Members of the Core Expert Panel: Timothy Beukelman, MD, MSCE, S. Louis Bridges Jr., MD, PhD, W. Winn Chatham, MD, Jeffrey R. Curtis, MD, MPH, Kenneth G. Saag, MD, MSc, Jasvinder A. Singh, MBBS, MPH (University of Alabama at Birmingham), Daniel E. Furst, MD, Harold E. Paulus, MD (University of California, Los Angeles), Ted Mikuls, MD, MSPH (participated in meetings only prior to June 2010; University of Nebraska, Omaha), Larry W. Moreland, MD (University of Pittsburgh, Pittsburgh, PA), James O'Dell, MD (University of Nebraska, Omaha), Maria Suarez-Almazor, MD, MPH (MD Anderson Cancer Center, Houston, TX).

  • Content-Specific Expert Advisors: Kevin L. Winthrop, MD, MPH (tuberculosis; Oregon Health and Science University, Portland), Michael Saag, MD (infections; University of Alabama at Birmingham).

Ancillary